Baseline characteristics
| Characteristics | Evaluable patients (n=127) |
| Age at diagnosis (years), median (range) | 48 (19–88) |
| Race | |
| White | 99 (86.1%) |
| Asian | 9 (7.8%) |
| Black | 5 (4.3%) |
| Hispanic | 2 (1.7%) |
| No data | 12 |
| BMI at diagnosis (kg/m2), median (range) | 24.7 (18.4–54.5) |
| Age of menarche (years), median (range) | 12 (10–15) |
| History of OCP use | 39/64 (60.9%) |
| Duration of OCP use (of users) (years), median (range) | 3.8 (0.3–15) |
| Parity | |
| Nulliparous | 30 (25.6%) |
| Parous | 87 (74.4%) |
| No data | 10 |
| Menopausal status | |
| Pre-menopausal | 91 (74.6%) |
| Post-menopausal | 31 (25.4%) |
| No data | 5 |
| Age of menopause (if post-menopausal) (years), median (range) | 52 (41–58) |
| History of HRT use prior to diagnosis of LGESS | 8/78 (10.3%) |
| Duration of HRT use (of users) (years), median (range) | 10 (7–10) |
| History of breast cancer | 11/119 (9.2%) |
| History of tamoxifen use | 5/121 (4.1%) |
| History of diabetes mellitus | 4/121 (3.3%) |
| BSO prior to diagnosis | 2 (1.6%) |
| Uterine tumor size (cm), median (range) | 5.5 (0.7–15.8) |
| FIGO stage* | |
| I | 74 (58.3%) |
| II | 23 (18.1%) |
| III | 17 (13.4%) |
| IV | 13 (10.2%) |
| Presence of LVSI | 79/96 (82.3%) |
| Mitoses, per 10 hpf, median (range) | 3 (0–10) |
| Ovary/ovaries preserved after hysterectomy | 10 (7.9%) |
| Residual tumor after primary surgical resection | 17 (13.4%) |
For yes/no variables, only ‘yes’ values are shown.
*2018 FIGO staging system used.
BMI, body mass index; BSO, bilateral salpingo-oophorectomy; FIGO, International Federation of Gynecology and Obstetrics; hpf, high power fields; HRT, hormone replacement therapy; LGESS, low-grade endometrial stromal sarcoma; LVSI, lymphovascular space invasion; OCP, oral contraceptive pills.